Compound prepn containing monopotassium glycyrrhizunate and its prepn and application

A technology of glycyrrhizic acid monopotassium salt and compound preparation, applied in the field of medicine, can solve problems such as low bioavailability, achieve the effects of good curative effect, inhibiting fibrosis, and alleviating hepatic cytoplasmic change and necrosis

Inactive Publication Date: 2006-03-01
山东山大康诺制药有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently available oral preparations of glycyrrhizic acid monopotassium salt are unilateral preparations of glycyrrhizic acid monopotassium salt, which has the disadvantage of low bioavailability in vivo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Take 10L of ethyl acetate and 10L of acetic acid and mix well. Under sterile conditions, take 500g of the monopotassium glycyrrhizinate M raw material that meets the national drug standards and add it to the ethyl acetate-acetic acid mixture, stir to dissolve the monopotassium glycyrrhizinate, remove the insolubles by conventional filtration, and let the filtrate stand for precipitation After the crystallization is complete, the crystallized solid is collected by conventional filtration to obtain a high-purity sterile raw material of monopotassium glycyrrhizinate.

Embodiment 2

[0037] Take 200g of monopotassium glycyrrhizinate aseptic raw materials, 2000g of glycine, 100g of L-cysteine ​​hydrochloride, 80g of sodium chloride, 80g of anhydrous sodium sulfite, and 15g of disodium edetate (for preparing 100000ml small-volume injection) for later use.

[0038] Add 85 liters of water for injection at 85°C to the concentrated preparation tank, then add edetate disodium, L-cysteine ​​hydrochloride, glycine, sodium chloride, anhydrous sodium sulfite, glycyrrhizic acid to the concentrated preparation tank in sequence by weight Stir the monopotassium salt fully to dissolve completely, then add activated carbon in an amount of 0.03% of the total volume of the preparation, heat to 86°C, keep warm for 25 minutes, cool down to 40°C, decarbonize the liquid medicine and filter it into the dilute preparation tank. Add water for injection in the tank to adjust the dosing volume, adjust the pH to 6.5, filter the liquid medicine through a conventional terminal, fill it i...

Embodiment 3

[0040] Get 150g of monopotassium glycyrrhizinate aseptic raw material, 1500g of glycine, 75g of L-cysteine ​​hydrochloride, 60g of sodium chloride, 60g of anhydrous sodium sulfite, 11g of disodium edetate (to prepare 1000 bottles of 250ml specification large-capacity injection )spare.

[0041] Add 210L of water for injection at 88°C to the concentrated preparation tank, and then add edetate disodium, L-cysteine ​​hydrochloride, glycine, sodium chloride, anhydrous sodium sulfite, glycyrrhizic acid to the concentrated preparation tank in sequence by weight Stir the monopotassium salt fully to dissolve completely, then add activated carbon in an amount of 0.035% of the total volume of the preparation, heat to 88°C, keep it warm for 30 minutes, cool down to 45°C, decarbonize the liquid medicine and filter it into the dilute preparation tank. Water for injection is added to the tank to adjust the pH to 6.3, and the medicinal solution is filtered through a conventional terminal, fil...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses one kind of compound preparation comprising monopotassium glycyrrhizunate 20-75 weight portions, glycine 1-800 weight portions, L-cysteine hydrochloride 10-28 weight portions, and one or two of sodium chloride 10-30 weight portions, anhydrous sodium sulfite 10-28 weight portions and disodium edetate 1-9 weight portions. The present invention discloses also its preparation process and application in preparing medicine for treating viral hepatitis, chronic unresolved hepatitis, chronic active hepatitis, etc. Compared with available monopotassium glycyrrhizunate orally taken preparation, the compound preparation of the present invention has the advantages of high curative effect, less side effect, fast acting, high bioavailability, etc.

Description

technical field [0001] The invention relates to a compound preparation containing glycyrrhizic acid monopotassium salt and its preparation method, and its preparation and treatment of viral hepatitis, chronic persistent hepatitis, chronic active hepatitis, acute and chronic hepatitis B, liver poisoning and initial liver cirrhosis Application in medicine; belongs to the technical field of medicine. Background technique [0002] Hepatitis is a common and frequently-occurring disease that seriously endangers human health. Acute hepatitis is generally caused by hepatitis virus. There are many causes of chronic hepatitis, such as: hepatitis virus, other liver diseases, drug factors, etc. Viral hepatitis is the main type of hepatitis patients in my country. Among the various types of viral hepatitis that have been found, hepatitis B and C are the most harmful to human health. [0003] Patients with hepatitis who have chronic liver inflammation for more than 6 months are called c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P1/16A61P31/14A61P31/20
Inventor 赵桂森冯军涛王超李春民李思林
Owner 山东山大康诺制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap